Skip to main content
SpringerLink
Log in

Cancer Immunotherapy Targeting Co-signal Molecules

  • Chapter
  • First Online:
Co-signal Molecules in T Cell Activation

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1189))

Abstract

Great success of immune checkpoint blockade represented by anti-PD-1 monoclonal antibodies (mAbs) has changed a landscape of cancer immunotherapy. There is no doubt about an importance of co-signal molecules as one of the most promising targets in anti-cancer drugs. However, it should be noted that the proportion of patients who have objective and durable responses to immune checkpoint blockade remains less than 30% in majority of cancers. Thus, in addition to refine the usage of existing drugs for checkpoint blockade, identification and characterization of novel checkpoint molecules other than CTLA-4 and PD-1 is a highly anticipated research subject. In addition, agonists of stimulatory co-signal molecules have a potential to further improve anti-tumor effects, rendering them attractive in research and drug development. In this chapter, functions of co-signal molecules in anti-tumor immunity in terms of pre-clinical animal models as well as clinical trials are described.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Andreae S, Piras F, Burdin N, Triebel F (2002) Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol 168:3874–3880

    Article  CAS  PubMed  Google Scholar 

  • Baixeras E et al (1992) Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 176:327–337

    Article  CAS  PubMed  Google Scholar 

  • Blackburn SD et al (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Publ Group 10:29–37

    CAS  Google Scholar 

  • Brignone C, Escudier B, Grygar C, Marcu M, Triebel F (2009) A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 15:6225–6231

    Article  CAS  PubMed  Google Scholar 

  • Brignone C et al (2010) First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8:71

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Brunet JF et al (1987) A new member of the immunoglobulin superfamily--CTLA-4. Nat Int Weekly J Sci 328:267–270

    CAS  Google Scholar 

  • Chambers CA, Allison JP (1999) Costimulatory regulation of T cell function. Curr Opin Cell Biol 11:203–210

    Article  CAS  PubMed  Google Scholar 

  • Chang C-H et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162:1229–1241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chauvin J-M et al (2015) TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest 125:2046–2058

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen AI et al (1999) Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 11:689–698

    Article  CAS  PubMed  Google Scholar 

  • Chen S et al (2015) Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res 3:149–160

    Article  CAS  PubMed  Google Scholar 

  • Chiba S et al (2012) Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Publ Group 13:832–842

    CAS  Google Scholar 

  • Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541–3543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cohen AD et al (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 5:e10436

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Collins AV et al (2002) The interaction properties of costimulatory molecules revisited. Immunity 17:201–210

    Article  CAS  PubMed  Google Scholar 

  • Curti BD et al (2013) OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 73:7189–7198

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dardalhon V et al (2010) Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol 185:1383–1392

    Article  CAS  PubMed  Google Scholar 

  • Dong H et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800

    Article  CAS  PubMed  Google Scholar 

  • Eggermont AMM et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:522–530

    Article  CAS  PubMed  Google Scholar 

  • Freeman GJ et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH (2010) TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 235:172–189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goding SR et al (2013) Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 190:4899–4909

    Article  CAS  PubMed  Google Scholar 

  • Gramaglia I, Weinberg AD, Lemon M, Croft M (1998) Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 161:6510–6517

    CAS  PubMed  Google Scholar 

  • Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hodi FS et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with Advanced melanoma treated with pembrolizumab. J Clin Oncol 34:1510–1517

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huang C-T et al (2004) Role of LAG-3 in regulatory T cells. Immunity 21:503–513

    Article  CAS  PubMed  Google Scholar 

  • Huang Y-H et al (2016) Corrigendum: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 536:359–359

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huard B, Gaulard P, Faure F, Hercend T, Triebel F (1994) Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 39:213–217

    Article  CAS  PubMed  Google Scholar 

  • Hui E et al (2017) T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355:1428–1433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Johnston RJ et al (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26:923–937

    Article  CAS  PubMed  Google Scholar 

  • Kano Y et al (2016) Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion. Cancer Sci 107:398–406

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Keler T et al (2003) Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol 171:6251–6259

    Article  CAS  PubMed  Google Scholar 

  • Kopf M et al (1999) OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 11:699–708

    Article  CAS  PubMed  Google Scholar 

  • Langer CJ et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:1497–1508

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Latchman Y et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261–268

    Article  CAS  PubMed  Google Scholar 

  • Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736

    Article  CAS  PubMed  Google Scholar 

  • Lee H-W et al (2002) 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 169:4882–4888

    Article  PubMed  Google Scholar 

  • Mallett S, Fossum S, Barclay AN (1990) Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor. EMBO J 9:1063–1068

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Martinet L, Smyth MJ (2015) Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 15:243–254

    Article  CAS  PubMed  Google Scholar 

  • Matsuzaki J et al (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 107:7875–7880

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McIntire JJ et al (2001) Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2:1109–1116

    Article  CAS  PubMed  Google Scholar 

  • Melero I et al (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682–685

    Article  CAS  PubMed  Google Scholar 

  • Monney L et al (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nat Int Weekly J Sci 415:536–541

    CAS  Google Scholar 

  • Nishimura H et al (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319–322

    Article  CAS  PubMed  Google Scholar 

  • Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T (2013) A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Publ Group 14:1212–1218

    CAS  Google Scholar 

  • Park J-J et al (2010) B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116:1291–1298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Parry RV et al (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25:9543–9553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pauken KE, Wherry EJ (2014) TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit. Cancer Cell 26:785–787

    Article  CAS  PubMed  Google Scholar 

  • Piconese S, Valzasina B, Colombo MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205:825–839

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Postow MA et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017

    Article  PubMed  PubMed Central  Google Scholar 

  • Prigent P, El mir S, Dréano M, Triebel F (1999) Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. Eur J Immunol 29:3867–3876

    Article  CAS  PubMed  Google Scholar 

  • Pulle G, Vidric M, Watts TH (2006) IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol 176:2739–2748

    Article  CAS  PubMed  Google Scholar 

  • Qureshi OS et al (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332:600–603

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rangachari M et al (2012) Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion. Nat Med 18:1394–1400

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526

    Article  CAS  PubMed  Google Scholar 

  • Robert C et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372:2521–2532

    Article  CAS  PubMed  Google Scholar 

  • Romano E et al (2014) MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a phase I trial. J Transl Med 12:97

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Sakuishi K et al (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187–2194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sánchez-Fueyo A et al (2003) Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 4:1093–1101

    Article  PubMed  Google Scholar 

  • Selby MJ et al (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1:32–42

    Article  CAS  PubMed  Google Scholar 

  • Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135–142

    Article  CAS  PubMed  Google Scholar 

  • Shrimali RK et al (2017) Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis. Cancer Immunol Res 5:755–766

    Article  CAS  PubMed  Google Scholar 

  • Tolcher AW et al (2017) Phase Ib study of Utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with Pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin Cancer Res 23:5349–5357

    Article  CAS  PubMed  Google Scholar 

  • Tone M et al (2003) Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. PNAS 100:15059–15064

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vetto JT et al (1997) Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. AJS 174:258–265

    Article  CAS  Google Scholar 

  • Vu MD et al (2007) OX40 costimulation turns off Foxp3+ Tregs. Blood 110:2501–2510

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang C, Lin GHY, McPherson AJ, Watts TH (2009) Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 229:192–215

    Article  CAS  PubMed  Google Scholar 

  • Waterhouse P et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985–988

    Article  CAS  PubMed  Google Scholar 

  • Weinberg AD et al (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164:2160–2169

    Article  CAS  PubMed  Google Scholar 

  • Wilcox RA, Tamada K, Strome SE, Chen L (2002a) Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 169:4230–4236

    Article  CAS  PubMed  Google Scholar 

  • Wilcox RA et al (2002b) Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol 168:4262–4267

    Article  CAS  PubMed  Google Scholar 

  • Wing K et al (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271–275

    Article  CAS  PubMed  Google Scholar 

  • Workman CJ, Dugger KJ, Vignali DAA (2002) Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol 169:5392–5395

    Article  CAS  PubMed  Google Scholar 

  • Ye Z et al (2002) Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 8:343–348

    Article  CAS  PubMed  Google Scholar 

  • Yearley JH et al (2017) PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in Cancer. Clin Cancer Res 23:3158–3167

    Article  CAS  PubMed  Google Scholar 

  • Yokosuka T et al (2012) Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 209:1201–1217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yu X et al (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Publ Group 10:48–57

    CAS  Google Scholar 

  • Zhou Q et al (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117:4501–4510

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu C et al (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6:1245–1252

    Article  CAS  PubMed  Google Scholar 

  • Zinselmeyer BH et al (2013) PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 210:757–774

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan

    Masao Nakajima & Koji Tamada

Authors
  1. Masao Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koji Tamada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Tamada .

Editor information

Editors and Affiliations

  1. Department of Molecular Immunology Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

    Miyuki Azuma

  2. Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan

    Hideo Yagita

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Nakajima, M., Tamada, K. (2019). Cancer Immunotherapy Targeting Co-signal Molecules. In: Azuma, M., Yagita, H. (eds) Co-signal Molecules in T Cell Activation. Advances in Experimental Medicine and Biology, vol 1189. Springer, Singapore. https://doi.org/10.1007/978-981-32-9717-3_11

Download citation

Publish with us

Policies and ethics

Search

Navigation